I was talking to a physician recently when the topic of SGLT2 inhibitors came up. He spoke about his experience with the drugs and how he felt that a lot of physicians had a negative feeling about the drug because of the chance of UTI’s. He felt that this is an overblown issue and that when it does occur, he can treat it easily and does not worry if the patient will "get it back again."
He also felt that the approval of dapagliflozin will be a benefit in helping clinicians become more aware and comfortable with the drug class, leading to a definite uptick in prescribing. We also discussed the history of the drug and he was impressed when I showed him an article written by our intern, Phuong Nguyen, and thought that it would be beneficial to our readers. Please check out the History of the SGLT2 Inhibitor Drug Class.